The cost of Leqvio can vary based on insurance coverage, pharmacy, and location. Without insurance, a single carton of Leqvio, which contains two pre-filled syringes, can cost around $5,000 to $6,000. For instance, one reported retail price for two 2 mL of 189 mg/2 mL solution vials was approximately $5,490 [1].
What financial assistance options are available for Leqvio?
For commercially insured patients, Novartis, the manufacturer of Leqvio, offers a savings program. This program can reduce out-of-pocket costs to as low as $20 per 12-month treatment period for eligible patients. Specific terms and conditions apply, and the program has a maximum annual savings limit [2].
How long does Leqvio treatment typically last?
Leqvio is administered by a healthcare professional via subcutaneous injection. Following the initial two doses given three months apart, patients typically receive a maintenance dose every six months [3].
What is the mechanism of action for Leqvio?
Leqvio works by reducing low-density lipoprotein cholesterol (LDL-C). It is an siRNA (small interfering RNA) therapeutic that inhibits the synthesis of PCSK9 protein in the liver. PCSK9 normally promotes the degradation of LDL receptors. By reducing PCSK9, Leqvio increases the number of LDL receptors on the liver surface, leading to increased clearance of LDL-C from the blood [4].
How does Leqvio compare to other cholesterol-lowering medications?
Leqvio offers a different approach compared to statins, which are the most common cholesterol-lowering drugs. Statins work by reducing cholesterol production in the liver. Leqvio, as an siRNA, targets the PCSK9 protein to enhance the liver's ability to remove LDL cholesterol. Leqvio is typically used in addition to maximally tolerated statin therapy for adults with homozygous familial hypercholesterolemia or those with atherosclerotic cardiovascular disease and hypercholesterolemia requiring additional LDL-C lowering [4].
When do patents for Leqvio expire?
Information on specific patent expiry dates for Leqvio can be found through patent tracking services. DrugPatentWatch.com is a resource that provides detailed information on drug patents and exclusivity [5].
Who are the key competitors in the PCSK9 inhibitor market?
The market for PCSK9 inhibitors includes injectable medications. Beyond Leqvio, other prominent PCSK9 inhibitors include Praluent (alirocumab) and Repatha (evolocumab) [6]. These are monoclonal antibodies, distinct in their mechanism from Leqvio's siRNA approach.
What are the clinical trial results for Leqvio?
Clinical trials for Leqvio have demonstrated significant reductions in LDL-C levels. For example, in the ORION-9, ORION-10, ORION-11, and ORION-8 studies, Leqvio showed consistent and substantial reductions in LDL-C across different patient populations, including those with primary hyperlipidemia and ASCVD [3].
What are the potential side effects of Leqvio?
Common side effects reported in clinical trials for Leqvio include injection site reactions, upper respiratory tract infections, influenza, and pain in the extremities [3]. Serious adverse events are rare.
What is the regulatory status of Leqvio?
Leqvio has received approval from major regulatory bodies. In the United States, it is approved by the Food and Drug Administration (FDA), and in Europe, it is approved by the European Medicines Agency (EMA) [3].
Can Leqvio be used in patients with heterozygous familial hypercholesterolemia?
Yes, Leqvio is indicated for adult patients with homozygous familial hypercholesterolemia (HoFH) and for adult patients with atherosclerotic cardiovascular disease (ASCVD) and hypercholesterolemia who require additional lowering of LDL-C [4]. While not a primary indication, its mechanism of action suggests potential benefits in other hypercholesterolemic states.
What are the administration requirements for Leqvio?
Leqvio must be administered by a healthcare professional. It is given as a subcutaneous injection [3].
Are there any contraindications for Leqvio?
Leqvio is contraindicated in patients with a known history of severe hypersensitivity to the drug or any of its excipients [3].
---
Sources
[1] https://www.goodrx.com/leqvio
[2] https://www.leqvio.com/savings-and-support
[3] https://www.janssen.com/leqvio/hcp/about-leqvio
[4] https://www.ema.europa.eu/en/medicines/human/EPAR/leqvio
[5] https://drugpatentwatch.com/
[6] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6778485/